NetworkNewsBreaks – Odyssey Health Inc. (ODYY) I
Post# of 85
(Total Views: 166)
Posted On: 10/06/2022 3:22:20 PM
NetworkNewsBreaks – Odyssey Health Inc. (ODYY) Issues Recap of Concussion Drug Development Program
Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today provided a recap of its concussion drug development program. Concussions affect millions worldwide and represent an ‘unmet’ medical need, while repetitive concussions can increase the risk of developing chronic traumatic encephalopathy (“CTE”) and other neuropsychiatric disorders. Since acquisition of the intellectual property and all rights to the drug on March 1, 2021, Odyssey has made significant progress in its development program. Among many key milestones provided in the update, the company announced successful completion of the pre-clinical toxicology program and IND enabling safety studies for a phase I human trial. Odyssey is currently communicating with the U.S. Food and Drug Administration (“FDA”) to present findings from the phase I trial. The company is also identifying phase II trial sites and creating study design in collaboration with medical leadership and advisors.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today provided a recap of its concussion drug development program. Concussions affect millions worldwide and represent an ‘unmet’ medical need, while repetitive concussions can increase the risk of developing chronic traumatic encephalopathy (“CTE”) and other neuropsychiatric disorders. Since acquisition of the intellectual property and all rights to the drug on March 1, 2021, Odyssey has made significant progress in its development program. Among many key milestones provided in the update, the company announced successful completion of the pre-clinical toxicology program and IND enabling safety studies for a phase I human trial. Odyssey is currently communicating with the U.S. Food and Drug Administration (“FDA”) to present findings from the phase I trial. The company is also identifying phase II trial sites and creating study design in collaboration with medical leadership and advisors.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)